Stock Events

Stock Events

Q32 Bio 

€4.16
0
+€0+0% Today

Statistics

Day High
4.23
Day Low
4.09
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DB0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is a leader in the development of gene-based therapies using CRISPR/Cas9 technology, directly competing with Homology's gene editing platform.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the gene editing space using CRISPR technology, similar to Homology Medicines, targeting genetic diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the same space as Homology Medicines for genetic disorder treatments.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy and gene editing, making it a direct competitor in Homology's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the genetic disease treatment market.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a biotechnology company focusing on the development, commercialization of gene therapies, directly competing with Homology's gene therapy approach.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, through its acquisition of Bamboo Therapeutics and other initiatives, has entered the gene therapy space, making it a competitor in the broader market that Homology Medicines operates in.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies, competes in the advanced therapy medicinal products space, including gene therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals, through its collaboration with CRISPR Therapeutics and focus on treating genetic diseases, competes in the same therapeutic areas as Homology Medicines.

About

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Show more...
CEO
Ms. Jodie Pope Morrison
Employees
24
Country
GB
ISIN
US7469641051

Listings

LSE
GB
0T6G.LSE
STU
DE
DB0.STU
XNAS
US
QTTB
F
DE
DB0.F

0 Comments

Share your thoughts

FAQ

What is Q32 Bio stock price today?▼
The current price of DB0.STU is €4.16 EUR — it has increased by +0% in the past 24 hours. Watch Q32 Bio stock price performance more closely on the chart.
What is Q32 Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Q32 Bio stocks are traded under the ticker DB0.STU.
How many employees does Q32 Bio have?▼
As of April 10, 2026, the company has 24 employees.
When did Q32 Bio complete a stock split?▼
Q32 Bio has not had any recent stock splits.
Where is Q32 Bio headquartered?▼
Q32 Bio is headquartered in Waltham, GB.